Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSOL 5%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E is a parenteral nutrition solution providing amino acids, electrolytes, and dextrose for intravenous infusion. It supplies essential and non-essential amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of acid-base balance and cellular function. Calcium is included for bone health and neuromuscular function.
Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.
Parenteral nutrition for patients requiring intravenous feeding when oral or enteral nutrition is not possible, insufficient, or contraindicated.,Adjunct to other nutritional support in conditions such as gastrointestinal tract obstruction, malabsorption, preoperative bowel rest, or severe catabolic states.
Total parenteral nutrition in patients with inadequate oral or enteral intake,Correction of negative nitrogen balance in malnourished patients
Administer intravenously. Dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 500-2000 m L per day, infused at a rate not exceeding 2-3 m L/kg/hour (or 2 mg/kg/min of amino acids), equivalent to 1-1.5 g/kg/day of amino acids and 3-7 g/kg/day of dextrose.
Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.
Not applicable as a single entity; components have variable half-lives: dextrose ~1-2h, amino acids ~1-3h for distribution, electrolytes vary. No terminal half-life defined.
The half-life of infused amino acids is not defined as they are endogenous compounds. However, the nitrogen from amino acids has a biological half-life of approximately 6-18 hours, depending on metabolic activity. As part of total parenteral nutrition, the elimination half-life of infused amino acids is influenced by protein turnover and catabolism.
Amino acids are metabolized via transamination and deamination pathways; dextrose is metabolized via glycolysis and the citric acid cycle; electrolytes are not metabolized but are utilized in physiological processes.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Excretion of nitrogenous waste as urea occurs renally.
Excretion depends on amino acid and electrolyte composition; nitrogen waste is eliminated renally as urea. Calcium and magnesium are primarily renally excreted; potassium is mostly renally eliminated. Dextrose is metabolized to CO2 and water. In renal impairment, accumulation may occur.
Excretion of infused amino acids is primarily renal, with small amounts lost via feces and skin. Approximately 85-95% of the nitrogen load is excreted in urine as urea, ammonia, and other nitrogenous wastes. Less than 5% is eliminated in feces.
Low for amino acids and electrolytes; calcium ~40% bound to albumin, magnesium ~30% bound, potassium not protein-bound.
Amino acids are not protein-bound; they exist free in plasma. Minimal reversible binding to albumin occurs for some amino acids, but overall binding is <10%.
Not defined as a composite; amino acids distribute into total body water (0.5-0.6 L/kg), calcium distributes into extracellular fluid (~0.2 L/kg), potassium intracellularly (~4 L/kg).
The volume of distribution for amino acids is approximately 0.3-0.4 L/kg, reflecting distribution primarily in extracellular fluid and to a lesser extent intracellularly.
100% (intravenous administration).
Intravenous: 100% bioavailability. Not administered via other routes; oral or enteral administration is not applicable due to hepatic first-pass metabolism and different pharmacokinetics.
Contraindicated in severe renal failure (e GFR < 30 m L/min/1.73 m²) without renal replacement therapy; if used, reduce dose by 50% for moderate impairment (e GFR 30-59 m L/min/1.73 m²) and monitor electrolytes.
In GFR < 50 m L/min: reduce infusion rate by 50% and monitor nitrogen balance. In ESRD on dialysis: use only if essential; typical dose 0.5-0.6 g/kg/day of amino acids with careful monitoring.
Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in Child-Pugh class B (reduce amino acid dose by 50-75%); no adjustment for Child-Pugh class A.
Contraindicated in severe hepatic failure (Child-Pugh C) due to risk of hepatic encephalopathy. In Child-Pugh A or B, use with caution and reduce dose by 30-50%; monitor ammonia levels.
Dose based on body weight: Amino acids: 1-3 g/kg/day; Dextrose: 5-20 g/kg/day. Initiate at lower end and increase gradually. Typical infusion rate: 1-2 m L/kg/hour, titrate to blood glucose and metabolic tolerance. Not recommended for neonates without risk-benefit assessment.
Infants and children: 1-2 g/kg/day of amino acids via total parenteral nutrition (TPN) as a 5% solution. Adjust based on age, weight, and clinical condition. Maximum infusion rate 0.1 g/kg/hour.
No specific dose adjustment, but use with caution due to potential age-related decline in renal function. Monitor fluid balance and renal function; start at lower doses (e.g., 500 m L/day) and adjust based on tolerance and clinical response.
Start at lower end of dosing; monitor renal function (creatinine clearance) and avoid fluid overload. Typical initial dose: 0.8-1 g/kg/day of amino acids, adjusted to tolerance and clinical response.
Not applicable. CLINIMIX E does not carry an FDA black box warning.
None.
Risk of infection due to catheter-related bloodstream infections; strict aseptic technique required.,Metabolic complications including hyperglycemia, hypoglycemia, electrolyte imbalances, and acid-base disturbances.,Hepatic and renal function monitoring required; adjust infusion rates accordingly.,Aluminum toxicity risk in patients with renal impairment; prolonged use may lead to bone disease.,Do not administer simultaneously with blood products through the same infusion line.
Use with caution in patients with renal impairment (risk of azotemia and electrolyte imbalances),Monitor serum electrolytes, blood glucose, and fluid balance regularly,Risk of hyperglycemia in diabetic patients; adjust insulin accordingly,Possible hyperammonemia, especially in patients with hepatic insufficiency,Contains aluminum; may accumulate in renal impairment, leading to osteomalacia or neurotoxicity
Hypersensitivity to any component of the solution.,Severe electrolyte disturbances or metabolic acidosis.,Anuria or severe renal impairment (unless dialyzed adequately).,Hepatic coma or severe hepatic insufficiency.,Uncorrected hyperglycemia or hyperosmolar coma.
Severe hepatic failure with encephalopathy,Severe uremia without dialysis,Inborn errors of amino acid metabolism,Hypersensitivity to any component
None; this is an intravenous solution providing nutrition. Do not consume oral nutrients without clinical guidance as it may interfere with nutritional balance.
No direct food interactions as Aminos 5% is administered intravenously. However, oral dietary intake must be coordinated with total parenteral nutrition to avoid excessive protein or electrolyte intake.
CLINIMIX E 4.25/5 contains amino acids, dextrose, and electrolytes, including calcium. No teratogenic effects have been reported in animal or human studies with standard components at physiological concentrations. However, calcium administration in the third trimester may be associated with neonatal hypocalcemia if maternal hypercalcemia occurs. No specific fetal risks are identified for the first two trimesters when used as indicated for parenteral nutrition.
Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with Aminosol 5%. Therefore, the teratogenic risk is not well defined. However, as a component of parenteral nutrition, it is considered essential for maternal and fetal health when indicated. Use only if clearly needed, weighing potential benefits against unknown risks. No specific trimester-associated risks have been reported.
Safety in breastfeeding is not established. Components excrete into milk in low amounts; no specific M/P ratio available. Parenteral nutrition use in lactating women should be with caution. Monitor infant for electrolyte imbalance.
Aminosolic 5% is a mixture of amino acids naturally present in human milk. Administration to lactating women may result in excretion of amino acids into breast milk, but the amounts are unlikely to be clinically significant. The M/P ratio is not known. Caution is advised, but use is generally considered compatible with breastfeeding when clinically indicated.
Pregnancy may increase fluid and electrolyte requirements. Glucose monitoring is essential as gestational diabetes may develop. Calcium dosing may need adjustment to avoid hypercalcemia. No specific dose changes for amino acids; follow standard parenteral nutrition guidelines. Adjust infusion rate based on clinical status and avoid iatrogenic hyperglycemia.
Standard adult dosing (5% solution, 500-1000 m L/day) may be used; however, increased fluid volume and metabolic demands in pregnancy may require dose adjustments. Monitor for fluid overload and adjust infusion rate accordingly. No specific dose adjustment recommendations are established; use caution and individualize based on clinical status.
This is a premixed parenteral nutrition solution containing amino acids, dextrose, electrolytes, and calcium. Do not add other medications or supplements without compatibility verification. Monitor serum electrolytes, glucose, and calcium levels regularly. Use inline filter; do not administer if precipitate is present. Contains sulfite-free formulation; safe for sulfite-sensitive patients.
Aminos 5% is a crystalline amino acid solution used for parenteral nutrition. In renal failure, adjust dose to limit nitrogen load; monitor BUN. In hepatic encephalopathy, consider branched-chain amino acid formulations. Do not administer concurrently with blood products through same IV line due to risk of agglutination. Infuse via central line if peripheral veins insufficient; peripheral administration requires adequate lipid-based calorie co-administration to prevent phlebitis.
This medication is given through a vein; do not stop or adjust the infusion rate on your own.,Report any signs of infection at the IV site (redness, swelling, pain) or allergic reactions (rash, difficulty breathing).,This solution provides complete nutrition; do not eat or drink without your doctor's approval.,Notify your doctor if you experience nausea, vomiting, headache, or unusual tiredness.
This solution provides essential building blocks (amino acids) for protein synthesis when you cannot eat.,Report any signs of infection at the IV site: redness, swelling, pain, or drainage.,Tell your doctor if you experience nausea, vomiting, or headache; dose adjustment may be needed.,Do not abruptly stop this infusion; it is part of your total nutrition plan.,Regular blood tests will be required to monitor kidney and liver function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSOL 5%, answered by our medical review team.
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E is a parenteral nutrition solution providing amino acids, electrolytes, and dextrose for intravenous infusion. It supplies essential and non-essential amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of acid-base balance and cellular function. Calcium is included for bone health and neuromuscular function.. AMINOSOL 5% is a Parenteral Nutrition Solution that works by Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSOL 5% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is: Administer intravenously. Dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 500-2000 m L per day, infused at a rate not exceeding 2-3 m L/kg/hour (or 2 mg/kg/min of amino acids), equivalent to 1-1.5 g/kg/day of amino acids and 3-7 g/kg/day of dextrose.. The standard adult dose of AMINOSOL 5% is: Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSOL 5% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 4.25/5 contains amino acids, dextrose, and electrolytes, including calcium. No teratogenic effects have been reported in animal or human studies with standard components. AMINOSOL 5% is classified as Category C. Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies hav. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.